Tags

Type your tag names separated by a space and hit enter

Frovatriptan for the acute treatment of migraine and prevention of predictable menstrual migraine.
Expert Rev Neurother. 2008 May; 8(5):723-36.ER

Abstract

Frovatriptan is a 5-HT(1B/1D) receptor agonist that belongs to the triptan therapeutic class. Relative to other triptans, frovatriptan has a long half-life (26 h) and a low incidence of migraine recurrence (17%). Frovatriptan is indicated for the acute treatment of migraine with or without aura, and has a relatively good safety and tolerability profile. Recent studies have also shown that a 6-day regimen of frovatriptan scheduled during the perimenstrual period significantly reduced the incidence and severity of menstrual migraine (MM; attacks that regularly start day -2 to +3 relative to menses). Prevention may be important because MM attacks have been characterized as being of longer duration, more severe and more refractory to treatment than non-MM attacks.

Authors+Show Affiliations

Elkind Headache Center, 12 North Seventh Avenue, Mount Vernon, NY 10550, USA. arthur.elkind@verizon.netNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18457529

Citation

Elkind, Arthur H., and E Anne MacGregor. "Frovatriptan for the Acute Treatment of Migraine and Prevention of Predictable Menstrual Migraine." Expert Review of Neurotherapeutics, vol. 8, no. 5, 2008, pp. 723-36.
Elkind AH, MacGregor EA. Frovatriptan for the acute treatment of migraine and prevention of predictable menstrual migraine. Expert Rev Neurother. 2008;8(5):723-36.
Elkind, A. H., & MacGregor, E. A. (2008). Frovatriptan for the acute treatment of migraine and prevention of predictable menstrual migraine. Expert Review of Neurotherapeutics, 8(5), 723-36. https://doi.org/10.1586/14737175.8.5.723
Elkind AH, MacGregor EA. Frovatriptan for the Acute Treatment of Migraine and Prevention of Predictable Menstrual Migraine. Expert Rev Neurother. 2008;8(5):723-36. PubMed PMID: 18457529.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Frovatriptan for the acute treatment of migraine and prevention of predictable menstrual migraine. AU - Elkind,Arthur H, AU - MacGregor,E Anne, PY - 2008/5/7/pubmed PY - 2008/6/5/medline PY - 2008/5/7/entrez SP - 723 EP - 36 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 8 IS - 5 N2 - Frovatriptan is a 5-HT(1B/1D) receptor agonist that belongs to the triptan therapeutic class. Relative to other triptans, frovatriptan has a long half-life (26 h) and a low incidence of migraine recurrence (17%). Frovatriptan is indicated for the acute treatment of migraine with or without aura, and has a relatively good safety and tolerability profile. Recent studies have also shown that a 6-day regimen of frovatriptan scheduled during the perimenstrual period significantly reduced the incidence and severity of menstrual migraine (MM; attacks that regularly start day -2 to +3 relative to menses). Prevention may be important because MM attacks have been characterized as being of longer duration, more severe and more refractory to treatment than non-MM attacks. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/18457529/Frovatriptan_for_the_acute_treatment_of_migraine_and_prevention_of_predictable_menstrual_migraine_ DB - PRIME DP - Unbound Medicine ER -